Eli Lilly has signed a $1.9 billion agreement with Ascidian Therapeutics to advance a pipeline of RNA exon editors specifically targeting inherited kidney diseases. This massive investment highlights a growing industry focus on high-precision genetic medicines that modify RNA rather than altering the underlying DNA sequence. Biotech developers should also note the simultaneous release of new open-source protein biology models, which are set to streamline the design of binders and protein function mapping in drug discovery.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
3
Ali NematiWritten by Ali
